News
-
-
PRESS RELEASE
Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline.
Andera Partners' portfolio company Tubulis acquired by Gilead, strengthening Gilead's oncology pipeline with innovative ADC technology -
-
PRESS RELEASE
Andera Partners’ Portfolio Company Exciva Secures €51 Million Series B to Advance Clinical Program for Alzheimer’s-Related Agitation
Andera Partners' portfolio company Exciva secures €51 million Series B funding for Alzheimer's-related agitation clinical program, led by Gimv and EQT Life Sciences -
-
-
-
PRESS RELEASE
Andera Partners Leads $67 Million Series A Financing in Spiro Medical to Develop a Neuromodulation System for Asthma
Andera Partners leads $67 million Series A financing in Spiro Medical to develop a Neuromodulation System for Asthma, aiming to revolutionize treatment. Key investors include Omega Funds and Sherpa Healthcare Partners -
-
PRESS RELEASE
Ipsen to acquire ImCheck Therapeutics, in Andera Partners’ portfolio, expanding its leadership in oncology, strengthening its pipeline
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology by acquiring all shares of ImCheck. Anticipated acquisition focuses on ICT01 program for acute myeloid leukemia. Transaction details and advisors highlighted
